As of May 2, 2023, the outbreak of the coronavirus disease (COVID-19) had been confirmed in almost every country in the world. The virus had infected over 687 million people worldwide, and the number of deaths had reached almost 6.87 million. The most severely affected countries include the U.S., India, and Brazil.

COVID-19: background information COVID-19 is a novel coronavirus that had not previously been identified in humans. The first case was detected in the Hubei province of China at the end of December 2019. The virus is highly transmissible and coughing and sneezing are the most common forms of transmission, which is similar to the outbreak of the SARS coronavirus that began in 2002 and was thought to have spread via cough and sneeze droplets expelled into the air by infected persons.

Naming the coronavirus disease Coronaviruses are a group of viruses that can be transmitted between animals and people, causing illnesses that may range from the common cold to more severe respiratory syndromes. In February 2020, the International Committee on Taxonomy of Viruses and the World Health Organization announced official names for both the virus and the disease it causes: SARS-CoV-2 and COVID-19, respectively. The name of the disease is derived from the words corona, virus, and disease, while the number 19 represents the year that it emerged.

This statistic depicts the total number of annual new HIV infections worldwide from 2000 to 2024. UNAIDS estimated that there were some *** million people worldwide that were newly infected with HIV in 2024. Total number of new HIV infections worldwideHuman immunodeficiency virus (HIV) is a condition that slowly destroys or impairs the body’s immune system. It is a retrovirus that slowly progresses through the various stages of the disease. As HIV reproduces, it mutates its structure, which makes it difficult to treat through drug therapy. Around **** million people were living with HIV worldwide as of 2024 with some **** million people accessing ART treatment. There are various types of ways to treat HIV. Antiviral treatment has been on the decline as combination therapy such as fixed-dose combinations become more popular. New HIV infections worldwide have been on the decline since 2000 from *** million new infections to *** million new infections in 2024. Many new infections occur in developing countries, especially those in low- and middle-income countries in Sub-Saharan Africa. Many of these individuals have no access to drugs or treatment that can make living with HIV more manageable. Children are also susceptible to infection, often from HIV-positive mothers during pregnancy, childbirth, or breastfeeding. There are approximately *** million children living with HIV globally.

Based on a comparison of coronavirus deaths in 210 countries relative to their population, Peru had the most losses to COVID-19 up until July 13, 2022. As of the same date, the virus had infected over 557.8 million people worldwide, and the number of deaths had totaled more than 6.3 million. Note, however, that COVID-19 test rates can vary per country. Additionally, big differences show up between countries when combining the number of deaths against confirmed COVID-19 cases. The source seemingly does not differentiate between "the Wuhan strain" (2019-nCOV) of COVID-19, "the Kent mutation" (B.1.1.7) that appeared in the UK in late 2020, the 2021 Delta variant (B.1.617.2) from India or the Omicron variant (B.1.1.529) from South Africa.

The difficulties of death figures

This table aims to provide a complete picture on the topic, but it very much relies on data that has become more difficult to compare. As the coronavirus pandemic developed across the world, countries already used different methods to count fatalities, and they sometimes changed them during the course of the pandemic. On April 16, for example, the Chinese city of Wuhan added a 50 percent increase in their death figures to account for community deaths. These deaths occurred outside of hospitals and went unaccounted for so far. The state of New York did something similar two days before, revising their figures with 3,700 new deaths as they started to include “assumed” coronavirus victims. The United Kingdom started counting deaths in care homes and private households on April 29, adjusting their number with about 5,000 new deaths (which were corrected lowered again by the same amount on August 18). This makes an already difficult comparison even more difficult. Belgium, for example, counts suspected coronavirus deaths in their figures, whereas other countries have not done that (yet). This means two things. First, it could have a big impact on both current as well as future figures. On April 16 already, UK health experts stated that if their numbers were corrected for community deaths like in Wuhan, the UK number would change from 205 to “above 300”. This is exactly what happened two weeks later. Second, it is difficult to pinpoint exactly which countries already have “revised” numbers (like Belgium, Wuhan or New York) and which ones do not. One work-around could be to look at (freely accessible) timelines that track the reported daily increase of deaths in certain countries. Several of these are available on our platform, such as for Belgium, Italy and Sweden. A sudden large increase might be an indicator that the domestic sources changed their methodology.

Where are these numbers coming from?

The numbers shown here were collected by Johns Hopkins University, a source that manually checks the data with domestic health authorities. For the majority of countries, this is from national authorities. In some cases, like China, the United States, Canada or Australia, city reports or other various state authorities were consulted. In this statistic, these separately reported numbers were put together. For more information or other freely accessible content, please visit our dedicated Facts and Figures page.

In March 2020, it was estimated that the infection rate for COVID-19 ranged between 1.5 and 3.5. In comparison, the seasonal flu had an infection rate of 1.3. Data is subject to change due to the developing situation with the coronavirus pandemic.

Rising infection rates could reignite virus COVID-19 is an infectious disease that continues to threaten different parts of the world simultaneously. The number of positive cases in the United States topped 5.5 million on August 22, 2020, and the potential for new waves of infection remains. In several U.S. states, the infection rate is higher than one, which means each infected person is passing the virus to more than one other person. When an infection rate is less than one, the outbreak will weaken because the viral pathogen is not as widely spread.

The importance of isolation Someone who has been diagnosed with COVID-19 can easily spread the virus to others. For this reason, patients are urged to self-isolate for around 14 days. To further reduce the risk of transmission, people who have been in close contact with a positive case should also self-isolate, even if they feel healthy. National testing programs make it easier to track the spread of the virus and are helping to flatten the infection curve. The U.S. had conducted more than 70 million coronavirus tests as of August 24, 2020 – the states of California and New York had performed more than any other.

In terms of the number of infected people, the novel coronavirus (SARS-CoV-2) ranked third among ten major virus outbreaks as of the end of January 2020. The virus, which originated from the Chinese city of Wuhan, has since spread to around 215 countries and territories worldwide.

China searching for disease’s origins The cumulative number of COVID-19 cases in China topped 89,000 on August 11, 2020. The SARS-CoV-2 virus and the infectious disease it causes were unknown before the outbreak began in China in December 2019. Experts from the World Health Organization are now working with Chinese counterparts to identify the origins of the virus. The most common symptoms reported by Chinese patients were fever, dry cough, and fatigue.

The rapid global spread of the virus In March 2020, it was estimated that the SARS-CoV-2 virus had an infection rate of between 1.5 and 3.5, which is higher than other outbreaks that have emerged worldwide in the past two decades. According to early estimates in January 2020, the case fatality rate was around two percent, but the spread of the coronavirus has overwhelmed many countries. The case fatality rate in China was as high as 5.5 percent in mid-April 2020.

The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.

Since late January, The Times has tracked cases of coronavirus in real time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.

We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists and government officials who would like access to the data to better understand the outbreak.

The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.

In 2023, in South Africa, there were around 2.7 HIV newly infected persons per every 1,000 inhabitants. This statistic depicts the countries with the highest incidence rates of new HIV infections worldwide as of 2023.

In 2023, in East and Southern Africa there was an average of 0.89 newly HIV infected persons per every 1,000 inhabitants. This statistic depicts the average prevalence of new HIV infections worldwide in 2023, by region and per 1,000 population.

Updates

• Notice of data discontinuation: Since the start of the pandemic, AP has reported case and death counts from data provided by Johns Hopkins University. Johns Hopkins University has announced that they will stop their daily data collection efforts after March 10. As Johns Hopkins stops providing data, the AP will also stop collecting daily numbers for COVID cases and deaths. The HHS and CDC now collect and visualize key metrics for the pandemic. AP advises using those resources when reporting on the pandemic going forward.

  • CDC Weekly case and death counts (national and state level)
  • CDC County level cases and deaths
  • HHS New hospital admissions
  • CDC NowCast COVID variant proportions (national and regional level)

• April 9, 2020

  • The population estimate data for New York County, NY has been updated to include all five New York City counties (Kings County, Queens County, Bronx County, Richmond County and New York County). This has been done to match the Johns Hopkins COVID-19 data, which aggregates counts for the five New York City counties to New York County.

• April 20, 2020

  • Johns Hopkins death totals in the US now include confirmed and probable deaths in accordance with CDC guidelines as of April 14. One significant result of this change was an increase of more than 3,700 deaths in the New York City count. This change will likely result in increases for death counts elsewhere as well. The AP does not alter the Johns Hopkins source data, so probable deaths are included in this dataset as well.

• April 29, 2020

  • The AP is now providing timeseries data for counts of COVID-19 cases and deaths. The raw counts are provided here unaltered, along with a population column with Census ACS-5 estimates and calculated daily case and death rates per 100,000 people. Please read the updated caveats section for more information.

• September 1st, 2020

  • Johns Hopkins is now providing counts for the five New York City counties individually.

• February 12, 2021

  • The Ohio Department of Health recently announced that as many as 4,000 COVID-19 deaths may have been underreported through the state’s reporting system, and that the "daily reported death counts will be high for a two to three-day period."
  • Because deaths data will be anomalous for consecutive days, we have chosen to freeze Ohio's rolling average for daily deaths at the last valid measure until Johns Hopkins is able to back-distribute the data. The raw daily death counts, as reported by Johns Hopkins and including the backlogged death data, will still be present in the new_deaths column.

• February 16, 2021

  - Johns Hopkins has reconciled Ohio's historical deaths data with the state.

  Overview

The AP is using data collected by the Johns Hopkins University Center for Systems Science and Engineering as our source for outbreak caseloads and death counts for the United States and globally.

The Hopkins data is available at the county level in the United States. The AP has paired this data with population figures and county rural/urban designations, and has calculated caseload and death rates per 100,000 people. Be aware that caseloads may reflect the availability of tests -- and the ability to turn around test results quickly -- rather than actual disease spread or true infection rates.

This data is from the Hopkins dashboard that is updated regularly throughout the day. Like all organizations dealing with data, Hopkins is constantly refining and cleaning up their feed, so there may be brief moments where data does not appear correctly. At this link, you’ll find the Hopkins daily data reports, and a clean version of their feed.

The AP is updating this dataset hourly at 45 minutes past the hour.

To learn more about AP's data journalism capabilities for publishers, corporations and financial institutions, go here or email kromano@ap.org.

Queries

Use AP's queries to filter the data or to join to other datasets we've made available to help cover the coronavirus pandemic

• Filter cases by state here

• Rank states by their status as current hotspots. Calculates the 7-day rolling average of new cases per capita in each state: https://data.world/associatedpress/johns-hopkins-coronavirus-case-tracker/workspace/query?queryid=481e82a4-1b2f-41c2-9ea1-d91aa4b3b1ac

• Find recent hotspots within your state by running a query to calculate the 7-day rolling average of new cases by capita in each county: https://data.world/associatedpress/johns-hopkins-coronavirus-case-tracker/workspace/query?queryid=b566f1db-3231-40fe-8099-311909b7b687&showTemplatePreview=true

• Join county-level case data to an earlier dataset released by AP on local hospital capacity here. To find out more about the hospital capacity dataset, see the full details.

• Pull the 100 counties with the highest per-capita confirmed cases here

• Rank all the counties by the highest per-capita rate of new cases in the past 7 days here. Be aware that because this ranks per-capita caseloads, very small counties may rise to the very top, so take into account raw caseload figures as well.

Interactive

The AP has designed an interactive map to track COVID-19 cases reported by Johns Hopkins.

@(https://datawrapper.dwcdn.net/nRyaf/15/)

Interactive Embed Code

<iframe title="USA counties (2018) choropleth map Mapping COVID-19 cases by county" aria-describedby="" id="datawrapper-chart-nRyaf" src="https://datawrapper.dwcdn.net/nRyaf/10/" scrolling="no" frameborder="0" style="width: 0; min-width: 100% !important;" height="400"></iframe><script type="text/javascript">(function() {'use strict';window.addEventListener('message', function(event) {if (typeof event.data['datawrapper-height'] !== 'undefined') {for (var chartId in event.data['datawrapper-height']) {var iframe = document.getElementById('datawrapper-chart-' + chartId) || document.querySelector("iframe[src*='" + chartId + "']");if (!iframe) {continue;}iframe.style.height = event.data['datawrapper-height'][chartId] + 'px';}}});})();</script>

Caveats

• This data represents the number of cases and deaths reported by each state and has been collected by Johns Hopkins from a number of sources cited on their website.
• In some cases, deaths or cases of people who've crossed state lines -- either to receive treatment or because they became sick and couldn't return home while traveling -- are reported in a state they aren't currently in, because of state reporting rules.
• In some states, there are a number of cases not assigned to a specific county -- for those cases, the county name is "unassigned to a single county"
• This data should be credited to Johns Hopkins University's COVID-19 tracking project. The AP is simply making it available here for ease of use for reporters and members.
• Caseloads may reflect the availability of tests -- and the ability to turn around test results quickly -- rather than actual disease spread or true infection rates.
• Population estimates at the county level are drawn from 2014-18 5-year estimates from the American Community Survey.
• The Urban/Rural classification scheme is from the Center for Disease Control and Preventions's National Center for Health Statistics. It puts each county into one of six categories -- from Large Central Metro to Non-Core -- according to population and other characteristics. More details about the classifications can be found here.

Johns Hopkins timeseries data - Johns Hopkins pulls data regularly to update their dashboard. Once a day, around 8pm EDT, Johns Hopkins adds the counts for all areas they cover to the timeseries file. These counts are snapshots of the latest cumulative counts provided by the source on that day. This can lead to inconsistencies if a source updates their historical data for accuracy, either increasing or decreasing the latest cumulative count. - Johns Hopkins periodically edits their historical timeseries data for accuracy. They provide a file documenting all errors in their timeseries files that they have identified and fixed here

Attribution

This data should be credited to Johns Hopkins University COVID-19 tracking project

The Hospital Acquired Infection Control Market Report Segments the Industry Into by Product and Services (Equipment, Services, Consumables), by Infection Type (Surgical Site Infections (SSI) Catheter-Associated Urinary Tract Infections (CAUTI) and More ), by End User (Hospitals and Intensive Care Units, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

According to Cognitive Market Research, the global Hospital-Acquired Infection Diagnostic market size is USD 29845.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 2.90% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 11938.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 1.1% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 8953.56 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 6864.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 1492.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.3% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 596.90 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.6% from 2024 to 2031.
Hospital held the highest Hospital-Acquired Infection Diagnostic market revenue share in 2024.

Market Dynamics of Hospital-Acquired Infection Diagnostic Market

Key Drivers for Hospital-Acquired Infection Diagnostic Market

Growing Prevalence of HAIs to Increase the Demand Globally

The Hospital-Acquired Infections Diagnostics Market is primarily driven by the ongoing increase in HAIs worldwide. The growing prevalence of these diseases highlights how important it is to have efficient diagnostic tools to recognize and treat infections contracted when a patient is in a medical facility. In the United States, an HAI affects around 1 in every 31 hospitalized patients at any given moment, according to Centers for Disease Control and Prevention (CDC) research. This means that 633,300 individuals get an HAI each year. Every year, the healthcare system in the United States sees more than a million HAIs. Tens of thousands of people lose their lives as a result of these illnesses every year, which can cause serious morbidity and death. According to estimates, HAIs cost billions of dollars a year.

Source: https://psnet.ahrq.gov/primer/health-care-associated-infections.

Rising Collaboration to Propel Market Growth

The increasing collaboration among the key players is expected to propel the market growth over the projected period. For instance, in February 2023, Roche announced that it has strengthened its research and innovation efforts by expanding its partnership with Janssen Biotech Inc. (Janssen) to develop companion diagnostics for targeted treatments. With several companion diagnostics technologies, such as immunohistochemistry (IHC), digital pathology, next-generation sequencing, polymerase chain reaction, and immunoassays, Roche and Janssen now have more opportunities to work together in the precision medicine space thanks to the new, enlarged partnership.

Source: https://diagnostics.roche.com/global/en/news-listing/2023/roche-expands-collaboration-with-janssen-to-advance-personalised.html.

Restraint Factor for the Hospital-Acquired Infection Diagnostic Market

High Cost and Lack of Skilled Personnel to Limit the Sales

The cost of advanced diagnostic equipment and technologies may prevent them from being widely used, particularly in poor countries with tighter budgets and in smaller healthcare facilities. The entire cost of healthcare may also rise due to the high cost of reagents and equipment. Furthermore, the proficiency of medical practitioners influences the efficacy of diagnostic procedures. Market expansion may be hampered by a lack of qualified laboratory workers and medical professionals versed in the use of cutting-edge diagnostic equipment.

Impact of Covid-19 on the Hospital-Acquired Infection Diagnostic Market

The hospital-acquired infection (HAI) diagnostic market has been impacted by the COVID-19 pandemic in several ways. While there have been several difficulties, there have also been fresh prospects and developments in healthcare procedures that may ultimately be advantageous to the market. Due to the pandemic, financial investments, manpower, and equipment were reallocated to the COVID-19 management effort. This change took resources and focus away from other areas of healthcar...

Chad TD: Newly Infected with HIV: Adults (Aged 15+) and Children (Aged 0-14) data was reported at 3,800.000 Number in 2022. This records a decrease from the previous number of 4,100.000 Number for 2021. Chad TD: Newly Infected with HIV: Adults (Aged 15+) and Children (Aged 0-14) data is updated yearly, averaging 8,700.000 Number from Dec 1990 (Median) to 2022, with 33 observations. The data reached an all-time high of 12,000.000 Number in 1994 and a record low of 3,800.000 Number in 2022. Chad TD: Newly Infected with HIV: Adults (Aged 15+) and Children (Aged 0-14) data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Chad – Table TD.World Bank.WDI: Social: Health Statistics. Number of adults (ages 15+) and children (ages 0-14) newly infected with HIV.;UNAIDS estimates.;;This indicator is related to Sustainable Development Goal 3.3.1 [https://unstats.un.org/sdgs/metadata/].

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) pandemic, has infected over 3 million people worldwide and caused over 200,000 deaths since it emerged in late 2019. There is an urgent need to develop therapies that can limit SARS-CoV-2 infection, replication, and pathogenesis. Due to the rapid emergence of SARS-CoV-2, there currently exists a lack in the knowledge of the host cellular pathways that sustain infection and contribute to pathogenesis. Here, we present a quantitative proteomics and phosphoproteomics survey of SARS-CoV-2 infection in Vero-E6 cells.

As of June 13, 2023, there have been almost 768 million cases of coronavirus (COVID-19) worldwide. The disease has impacted almost every country and territory in the world, with the United States confirming around 16 percent of all global cases.

COVID-19: An unprecedented crisis Health systems around the world were initially overwhelmed by the number of coronavirus cases, and even the richest and most prepared countries struggled. In the most vulnerable countries, millions of people lacked access to critical life-saving supplies, such as test kits, face masks, and respirators. However, several vaccines have been approved for use, and more than 13 billion vaccine doses had already been administered worldwide as of March 2023.

The coronavirus in the United Kingdom Over 202 thousand people have died from COVID-19 in the UK, which is the highest number in Europe. The tireless work of the National Health Service (NHS) has been applauded, but the country’s response to the crisis has drawn criticism. The UK was slow to start widespread testing, and the launch of a COVID-19 contact tracing app was delayed by months. However, the UK’s rapid vaccine rollout has been a success story, and around 53.7 million people had received at least one vaccine dose as of July 13, 2022.

Coronavirus Infection Market Outlook

The coronavirus infection market size was valued at approximately USD 18.9 billion globally in 2023 and is expected to reach USD 36.7 billion by 2032, growing at a CAGR of 7.8%. The surge in market size is driven by several factors including advancements in diagnostic methods, increasing investments in healthcare infrastructure, and growing awareness about viral prevention and treatment.

One of the primary growth factors in the coronavirus infection market is the rapid advancement in diagnostic technologies. The evolution of molecular tests, serology tests, and antigen tests has played a pivotal role in the early and accurate detection of coronavirus infections. The ability to quickly identify the virus has enabled timely intervention, which is crucial in controlling the spread of the disease. Moreover, continuous innovations and the introduction of point-of-care testing have made these diagnostics more accessible, further driving market growth.

Another significant growth factor is the increased funding and investments from governments and private organizations towards coronavirus treatment and prevention. The global health crisis has led to unprecedented financial support for research and development in antiviral medications, monoclonal antibodies, and immunomodulators. This influx of funds is not only accelerating the development of new treatments but also enhancing the capabilities of healthcare infrastructure worldwide. The improvement in hospital facilities and the establishment of specialized research institutes are expected to sustain the market growth over the forecast period.

The growing prevalence of coronavirus infections and the subsequent demand for effective treatments have also contributed to market expansion. The pandemic has highlighted the need for comprehensive supportive care and the development of therapies to manage symptoms and complications. As a result, there is a heightened focus on creating a robust pipeline of therapeutic options. The diversification of treatment methods, including antiviral drugs and immunomodulators, is anticipated to provide a significant boost to the market. Additionally, the rising awareness among the population about the importance of early diagnosis and treatment is fostering market growth.

Regionally, North America holds a substantial share of the coronavirus infection market, attributed to its well-established healthcare infrastructure and high healthcare expenditure. The region has been at the forefront of adopting advanced diagnostic and treatment methods, further propelling market growth. Europe follows closely, driven by extensive research activities and strong government support for healthcare initiatives. The Asia Pacific region is expected to witness the highest growth rate, owing to the increasing prevalence of coronavirus infections, expanding healthcare facilities, and rising investments in healthcare by both governmental and private entities.

Diagnostic Method Analysis

The diagnostic methods segment of the coronavirus infection market is categorized into molecular tests, serology tests, and antigen tests. Molecular tests, which include RT-PCR, are considered the gold standard for coronavirus detection. These tests are highly accurate and can detect the virus even in asymptomatic individuals, enabling early intervention and isolation. The demand for molecular tests surged during the pandemic and continues to grow as new variants of the virus emerge. Technological advancements in PCR techniques and the development of rapid PCR tests are expected to drive this segment's growth further.

Serology tests play a crucial role in identifying past infections and understanding the immune response to coronavirus. These tests are essential for epidemiological studies and vaccine efficacy assessments. The growing need for immunity passports and the monitoring of vaccine-induced immunity are key factors driving the demand for serology tests. Additionally, the increasing deployment of serology tests in large-scale population screening programs is expected to contribute significantly to market growth. Innovations in serology testing, such as multiplex assays, are enhancing their accuracy and utility.

Antigen tests offer a faster and more cost-effective alternative to molecular tests for the detection of active coronavirus infections. These tests are particularly useful in settings where rapid results are needed, such as airports, schools, and workplaces. The ease of use and quick turnaround time of antigen tests have led to their wides

The global Infection Prevention Market is estimated to be valued at USD 44,535.9 million in 2025 and is projected to reach USD 65,292.8 million by 2035, registering a compound annual growth rate (CAGR) of 3.9% over the forecast period.

Metric	Value
Industry Size (2025E)	USD 44,535.9 million
Industry Value (2035F)	USD 65,292.8 million
CAGR (2025 to 2035)	3.9%

Country-wise Insights

Year	CAGR (2025 to 2035)
2025 to 2035	3.3%

Year	CAGR (2025 to 2035)
2025 to 2035	3.1%

Year	CAGR (2025 to 2035)
2025 to 2035	5.5%

Year	CAGR (2025 to 2035)
2025 to 2035	5.8%

Year	CAGR (2025 to 2035)
2025 to 2035	3.5%

The global infection control surveillance solutions market size is expected to reach USD 1.23 billion by 2028 from USD 580.42 million in 2022, growing at a CAGR of 13.47%.

BackgroundFlavivirus pose a continued threat to global health, yet their worldwide burden and trends remain poorly quantified. We aimed to evaluate the global, regional, and national incidence of three common flavivirus infections (Dengue, yellow fever, and Zika) from 2011 to 2021.MethodsData on the number and rate of incidence for the three common flavivirus infection in 204 countries and territories were retrieved from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021. The estimated annual percent change (EAPC) was calculated to quantify the temporal trend during 2011–2016, 2016–2019, and 2019–2021, respectively.ResultsIn 2021, an estimated 59,220,428 individuals were infected globally, comprising 58,964,185 cases of dengue, 86,509 cases of yellow fever, and 169,734 cases of Zika virus infection. The age-standardized incidence rate (ASIR) of the three common flavivirus infections increased by an annual average of 5.08% (95% CI 4.12 to 6.05) globally from 2011 to 2016, whereas decreased by an annual average of −8.37% (95% CI −12.46 to −4.08) per year between 2016 to 2019. The ASIR remained stable during 2019–2021, with an average change of 0.69% (95% CI −0.96 to 2.37) per year globally for the three common flavivirus infections. Regionally, the burden of the three common flavivirus infections was primarily concentrated in those regions with middle income, such as South Asia, Southeast Asia, and Tropical Latin America. Additionally, at the country level, there was an inverted “U” relationship between the SDI level and the ASI. Notably, an increase in the average age of infected cases has been observed worldwide, particularly in higher-income regions.ConclusionFlavivirus infections are an expanding public health concern worldwide, with considerable regional and demographic variation in the incidence. Policymakers and healthcare providers must stay vigilant regarding the impact of COVID-19 and other environmental factors on the risk of flavivirus infection and be prepared for potential future outbreaks.

France FR: Newly Infected with HIV: Adults: Aged 15-24 data was reported at 1,000.000 Number in 2022. This stayed constant from the previous number of 1,000.000 Number for 2021. France FR: Newly Infected with HIV: Adults: Aged 15-24 data is updated yearly, averaging 1,000.000 Number from Dec 1990 (Median) to 2022, with 33 observations. The data reached an all-time high of 1,000.000 Number in 2022 and a record low of 1,000.000 Number in 2022. France FR: Newly Infected with HIV: Adults: Aged 15-24 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s France – Table FR.World Bank.WDI: Social: Health Statistics. Number of young people (ages 15-24) newly infected with HIV.;UNAIDS estimates.;;This indicator is related to Sustainable Development Goal 3.3.1 [https://unstats.un.org/sdgs/metadata/].

Italy IT: Newly Infected with HIV: Adults: Aged 15-24 data was reported at 200.000 Number in 2022. This stayed constant from the previous number of 200.000 Number for 2021. Italy IT: Newly Infected with HIV: Adults: Aged 15-24 data is updated yearly, averaging 500.000 Number from Dec 1990 (Median) to 2022, with 33 observations. The data reached an all-time high of 1,000.000 Number in 1997 and a record low of 200.000 Number in 2022. Italy IT: Newly Infected with HIV: Adults: Aged 15-24 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Italy – Table IT.World Bank.WDI: Social: Health Statistics. Number of young people (ages 15-24) newly infected with HIV.;UNAIDS estimates.;;This indicator is related to Sustainable Development Goal 3.3.1 [https://unstats.un.org/sdgs/metadata/].